Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II)

NCT00031681 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00031681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2001
Completion date
Not reported
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult primary liver cancer, carcinoma of the appendix, estrogen receptor-negative breast cancer, extensive stage small cell lung cancer, gastrointestinal stromal tumor, her2-negative breast cancer, metastatic gastrointestinal carcinoid tumor, ovarian sarcoma, ovarian stromal cancer, progesterone receptor-negative breast cancer, recurrent adenoid cystic carcinoma of the oral cavity, recurrent adult primary liver cancer, recurrent anal cancer, recurrent basal cell carcinoma of the lip, recurrent borderline ovarian surface epithelial-stromal tumor, recurrent breast cancer, recurrent cervical cancer, recurrent colon cancer, recurrent endometrial carcinoma, recurrent esophageal cancer, recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity, recurrent extrahepatic bile duct cancer, recurrent gallbladder cancer, recurrent gastric cancer, recurrent gastrointestinal carcinoid tumor, recurrent inverted papilloma of the paranasal sinus and nasal cavity, recurrent lymphoepithelioma of the nasopharynx, recurrent lymphoepithelioma of the oropharynx, recurrent metastatic squamous neck cancer with occult primary, recurrent midline lethal granuloma of the paranasal sinus and nasal cavity, recurrent mucoepidermoid carcinoma of the oral cavity, recurrent non-small cell lung cancer, recurrent ovarian epithelial cancer, recurrent ovarian germ cell tumor, recurrent pancreatic cancer, recurrent prostate cancer, recurrent rectal cancer, recurrent salivary gland cancer, recurrent small cell lung cancer, recurrent small intestine cancer, recurrent squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, recurrent verrucous carcinoma of the larynx, recurrent verrucous carcinoma of the oral cavity, small intestine adenocarcinoma, small intestine leiomyosarcoma, small intestine lymphoma, stage iv adenoid cystic carcinoma of the oral cavity, stage iv anal cancer, stage iv basal cell carcinoma of the lip, stage iv borderline ovarian surface epithelial-stromal tumor, stage iv breast cancer, stage iv colon cancer, stage iv endometrial carcinoma, stage iv esophageal cancer, stage iv esthesioneuroblastoma of the paranasal sinus and nasal cavity, stage iv gastric cancer, stage iv inverted papilloma of the paranasal sinus and nasal cavity, stage iv lymphoepithelioma of the nasopharynx, stage iv lymphoepithelioma of the oropharynx, stage iv midline lethal granuloma of the paranasal sinus and nasal cavity, stage iv mucoepidermoid carcinoma of the oral cavity, stage iv non-small cell lung cancer, stage iv ovarian epithelial cancer, stage iv ovarian germ cell tumor, stage iv pancreatic cancer, stage iv prostate cancer, stage iv rectal cancer, stage iv salivary gland cancer, stage iv squamous cell carcinoma of the hypopharynx, stage iv squamous cell carcinoma of the larynx, stage iv squamous cell carcinoma of the lip and oral cavity, stage iv squamous cell carcinoma of the nasopharynx, stage iv squamous cell carcinoma of the oropharynx, stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity, stage iv verrucous carcinoma of the larynx, stage iv verrucous carcinoma of the oral cavity, stage iva cervical cancer, stage ivb cervical cancer, triple-negative breast cancer, unresectable extrahepatic bile duct cancer, unresectable gallbladder cancer, unspecified adult solid tumor, protocol specific, untreated metastatic squamous neck cancer with occult primary